Inhibitors of influenza viruses replication: a patent evaluation (WO2013019828)

Bibliography

• Fouchier RA, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 2005;79:2814-22
   PubMed Web of Science ®Google Scholar
• Zhu X, Yu W, Mcbride R, et al. Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Proc Natl Acad Sci USA 2013;110:1458-63
   PubMedGoogle Scholar
• Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006;443:45-9
   PubMed Web of Science ®Google Scholar
• Laver G, Garman E. Pandemic influenza: its origin and control. Microbes Infect 2002;4:1309-16
   Google Scholar
• H5N1 avian influenza: timeline of major events. Word Health Organization. Available from: http://www.who.int/influenza/H5N1_avian_influenza_update_20121217b.pdf [Last update 17 December 2012]
   Google Scholar
• Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009;459:931-9
   PubMed Web of Science ®Google Scholar
• Wu S, Wu F, He J. Emerging risk of H7N9 influenza in China. Lancet 2013;381:1539-40
   PubMed Web of Science ®Google Scholar
• Johansson BE, Brett IC. Changing perspective on immunization against influenza. Vaccine 2007;25:3062-5
   PubMed Web of Science ®Google Scholar
• Leonov H, Astrahan P, Krugliak M, et al. How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? J Am Chem Soc 2011;133:9903-11
   Web of Science ®Google Scholar
• Mossong J, Opp M, Gerloff N, et al. Emergence of oseltamivir-resistant influenza A H1N1 virus during the 2007-2008 winter season in Luxembourg: clinical characteristics and epidemiology. Antiviral Res 2009;84:91-4
   Google Scholar
• Boltz DA, Aldridge JR Jr, Webster RG, et al. Drugs in development for influenza. Drugs 2010;70:1349-62
   PubMed Web of Science ®Google Scholar
• Sleeman K, Mishin VP, Deyde VM, et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 2010;54:2517-24
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010;107:882-7
   PubMed Web of Science ®Google Scholar
• Moss RB, Hansen C, Sanders RL, et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012;206:1844-51
   PubMed Web of Science ®Google Scholar
• Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 2009;4:e7838
   PubMed Web of Science ®Google Scholar
• Xie Y, Gong J, Li M, et al. The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase. Curr Med Chem 2011;18:1050-66
   Google Scholar
• Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA 2009;106:8701-6
   Google Scholar
• Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007;13:3531-42
   PubMedGoogle Scholar
• Krug RM, Aramini JM. Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci 2009;30:269-77
   PubMed Web of Science ®Google Scholar
• Chaumeil H, Signorella S, Le Drian C. Suzuki cross-coupling reaction of sterically hindered aryl boronates with 3-iodo-4-methoxybenzoic acid methylester. Tetrahedron 2000;56:9655-62
   Web of Science ®Google Scholar
• Noah JW, Severson W, Noah DL, et al. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res 2007;73:50-9
   PubMed Web of Science ®Google Scholar
• Wagaman PC, Leong MA, Simmen KA. Development of a novel influenza A antiviral assay. J Virol Methods 2002;105:105-14
   PubMed Web of Science ®Google Scholar
• Glaab T, Taube C, Braun A, et al. Invasive and noninvasive methods for studying pulmonary function in mice. Respir Res 2007;8:63
   PubMed Web of Science ®Google Scholar
• Prichard MN, Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990;14:181-205
   PubMed Web of Science ®Google Scholar
• Stouffer AL, Acharya R, Salom D, et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008;451:596-9
   PubMed Web of Science ®Google Scholar
• Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008;451:591-5
   PubMed Web of Science ®Google Scholar
• Cady SD, Mishanina TV, Hong M. Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding. J Mol Biol 2009;385:1127-41
   PubMed Web of Science ®Google Scholar
• Portela A, Digard P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 2002;83:723-34
   PubMed Web of Science ®Google Scholar
• Ye Q, Krug RM, Tao YJ. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 2006;444:1078-82
   PubMed Web of Science ®Google Scholar
• Ng AK, Zhang H, Tan K, et al. Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design. FASEB J 2008;22:3638-47
   PubMed Web of Science ®Google Scholar
• Yeh JY, Coumar MS, Horng JT, et al. Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives. J Med Chem 2010;53:1519-33
   PubMed Web of Science ®Google Scholar
• Yamada K, Koyama H, Hagiwara K, et al. Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase. Microbes Infect 2012;14:740-7
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Minakuchi M, Kawaguchi A, et al. Structure-based discovery of anti-influenza virus A compounds among medicines. Biochim Biophys Acta 2012;1820:90-5
   PubMed Web of Science ®Google Scholar
• Ghanem A, Mayer D, Chase G, et al. Peptide-mediated interference with influenza A virus polymerase. J Virol 2007;81:7801-4
   PubMed Web of Science ®Google Scholar
• Muratore G, Goracci L, Mercorelli B, et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci USA 2012;109:6247-52
   PubMed Web of Science ®Google Scholar
• Salituro F, Farmer L, Bethiel R, et al. Azaindoles useful as inhibitors of JAK and other protein kinases. WO2005095400; 2005
   Google Scholar
• Kumar N, Liang Y, Parslow TG. Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication. J Virol 2011;85:2818-27
   Google Scholar